Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28818701 | 0.84 | MAOB (0.46) | MRGPRX4HPGDSMN1; SMN2 | |
| SCHEMBL29108709 | 0.84 | FOLH1 (0.59) | FOLH1CA1CA2CA9KMT2A | |
| SCHEMBL35452 | 0.82 | FOLH1 (0.58) | FOLH1MRGPRX4CA1CA2CA9 | |
| SCHEMBL22623401 | 0.82 | FOLH1 (0.58) | FOLH1MRGPRX4CA1CA2CA9 | |
| SCHEMBL31401245 | 0.82 | FOLH1 (0.58) | FOLH1MRGPRX4CA1CA2CA9 | |
| SCHEMBL31720548 | 0.82 | FOLH1 (0.58) | FOLH1CA1CA2CA9KMT2A | |
| SCHEMBL6011976 | 0.81 | FOLH1 (0.56) | FOLH1MRGPRX4CA1CA2CA9 | |
| SCHEMBL5146595 | 0.80 | CYP19A1 (0.40) | CA1CA2CA9 | |
| SCHEMBL5969642 | 0.80 | LOXL2 (0.62) | FOLH1MRGPRX4CA1CA2CA9 | |
| SCHEMBL14165021 | 0.80 | KMT2A (0.46) | MEN1NPC1HPGDRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113905785-A | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2022-01-07 | — | — | CN | claimed |
| CN-113905785-A | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9790183-B2 | Pyridyl inhibitors of hedgehog signalling | GENENTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
| CN-101801949-B | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| CN-101801949-A | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2010-08-11 | — | — | CN | disclosed |
| CN-101657449-A | diphenyl-dihydro-imidazopyridinones | HOFFMANN LA ROCHE CH | 2010-02-24 | — | — | CN | disclosed |
| EP-1177169-A1 | 6- [(ARYL AND HETEROARYL)OXY] METHYL]NAPHTHALENE -2-CARBOXIMIDAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-SYNTHELABO (FR) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066545-A1 | 6-[[(ARYL AND HETEROARYL)OXY] METHYL]NAPHTHALENE -2-CARBOXIMIDAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-SYNTHELABO (FR) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | FOLH1 708/4885MRGPRX4 40/4885CA1 3188/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | FOLH1 708/4885MRGPRX4 40/4885CA1 3188/4885 |
| US-20180029984-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | FOLH1 2409/4885MRGPRX4 401/4885CA1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.